Based on the literature to date, Nakamaki et al. 31 reported a case in which the MS4A1 gene was deleted after rituximab-containing chemotherapy for the treatment of diffuse large B-cell lymphoma (DLBCL). This evidence concerns the gene MS4A1 and diffuse large B-cell lymphoma.